Table 1.
Open in new tab

Nitazoxanide susceptibility (mg/L) of C. difficile PCR ribotypes, including those with reduced metronidazole susceptibility (CD-RM)

Epidemic C. difficile PCR ribotypes 001, 027 and 106
2008 (n = 24)2005 (n = 33)CD-RM, 2005 and 2008 (n = 39)Remainder of the top 10 most common C. difficile PCR ribotypes (n = 31)
MIC50 (metronidazole MIC50)0.03 (2)0.03 (2)0.03 (4)0.03 (0.5)
MIC900.060.1250.1250.06
Range0.03–0.1250.03–0.250.03–0.250.03–0.5a
Geometric mean MIC0.0360.0380.0370.034
Epidemic C. difficile PCR ribotypes 001, 027 and 106
2008 (n = 24)2005 (n = 33)CD-RM, 2005 and 2008 (n = 39)Remainder of the top 10 most common C. difficile PCR ribotypes (n = 31)
MIC50 (metronidazole MIC50)0.03 (2)0.03 (2)0.03 (4)0.03 (0.5)
MIC900.060.1250.1250.06
Range0.03–0.1250.03–0.250.03–0.250.03–0.5a
Geometric mean MIC0.0360.0380.0370.034

aIncludes toxin A−B− C. difficile PCR ribotype 010 (metronidazole MIC = 8–16 mg/L)—nitazoxanide MIC = 0.5 mg/L.

Table 1.
Open in new tab

Nitazoxanide susceptibility (mg/L) of C. difficile PCR ribotypes, including those with reduced metronidazole susceptibility (CD-RM)

Epidemic C. difficile PCR ribotypes 001, 027 and 106
2008 (n = 24)2005 (n = 33)CD-RM, 2005 and 2008 (n = 39)Remainder of the top 10 most common C. difficile PCR ribotypes (n = 31)
MIC50 (metronidazole MIC50)0.03 (2)0.03 (2)0.03 (4)0.03 (0.5)
MIC900.060.1250.1250.06
Range0.03–0.1250.03–0.250.03–0.250.03–0.5a
Geometric mean MIC0.0360.0380.0370.034
Epidemic C. difficile PCR ribotypes 001, 027 and 106
2008 (n = 24)2005 (n = 33)CD-RM, 2005 and 2008 (n = 39)Remainder of the top 10 most common C. difficile PCR ribotypes (n = 31)
MIC50 (metronidazole MIC50)0.03 (2)0.03 (2)0.03 (4)0.03 (0.5)
MIC900.060.1250.1250.06
Range0.03–0.1250.03–0.250.03–0.250.03–0.5a
Geometric mean MIC0.0360.0380.0370.034

aIncludes toxin A−B− C. difficile PCR ribotype 010 (metronidazole MIC = 8–16 mg/L)—nitazoxanide MIC = 0.5 mg/L.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close